Jardiance Archives -

Boehringer Ingelheim, Biberach, Germany, February 2007

Boehringer Ingelheim says it is planning to invest a hefty €25 billion ($27 billion) in its pipeline over

Boehringer plans €25bn R&D spend, fuelled by Jardiance

https://pharmaphorum.com/news/boehringer-plans-e25bn-rd-spend-fuelled-by-jardiance/

Market Access/ News/ News

Jardiance pulls ahead of Forxiga with heart failure approval in EU

Phil Taylor AstraZeneca, Boehringer Ingelheim, Eli Lilly, Entresto, heart failure, Jardiance, Novartis 0 Comment

Boehringer Ingelheim and Eli Lilly’s SGLT2 inhibitor Jardiance has become the first drug in the class to be

Jardiance pulls ahead of Forxiga with heart failure approval in EU

https://pharmaphorum.com/news/jardiance-pulls-ahead-of-forxiga-in-european-heart-failure-market/

News/ News/ R&D

Stage set for Jardiance to become universal heart failure drug

Phil Taylor AstraZeneca, Boehringer Ingelheim, Eli Lilly, Farxiga, heart failure, Jardiance 0 Comment

Boehringer Ingelheim and Eli Lilly have published data for their SGLT2 inhibitor Jardiance in acute heart failure, setting

Stage set for Jardiance to become universal heart failure drug

https://pharmaphorum.com/news/stage-set-for-jardiance-to-become-universal-heart-failure-drug/

Market Access/ News/ News

Jardiance gets parity with Farxiga in US as FDA clears use in heart failure

Phil Taylor AstraZeneca, Boehringer Ingelheim, cardiology, Eli Lilly, Farxiga, fda, heart failure, Jardiance, regulatory approval 0 Comment

Eli Lilly and Boehringer Ingelheim have claimed FDA approval for their diabetes therapy Jardiance in heart failure with

Jardiance gets parity with Farxiga in US as FDA clears use in heart failure

https://pharmaphorum.com/news/jardiance-gets-parity-with-farxiga-in-us-as-fda-clears-use-in-heart-failure/

Ardelyx’s-ambition-to-revolutionise-kidney-treatment

News/ News/ Sales and Marketing

AZ gets European approvals for Forxiga in chronic kidney disease

Phil Taylor AstraZeneca, Boehringer Ingelheim, chronic kidney disease, Eli Lilly, EU, Farxiga, Forxiga, Jardiance, UK 0 Comment

AstraZeneca’s Forxiga has become the first SGLT2 inhibitor to be approved in Europe for use in people with

AZ gets European approvals for Forxiga in chronic kidney disease

https://pharmaphorum.com/news/az-gets-european-approvals-for-forxiga-in-chronic-kidney-disease/

News/ News/ R&D

Boehringer, Lilly hail Jardiance data in hard-to-treat heart failure

Phil Taylor AstraZeneca, Boehringer Ingelheim, Eli Lilly, Entresto, Farxiga, heart failure, Jardiance, Novartis 0 Comment

Boehringer Ingelheim and Eli Lilly have the results they were hoping for in a large-scale study of Jardiance

Boehringer, Lilly hail Jardiance data in hard-to-treat heart failure

https://pharmaphorum.com/news/boehringer-lilly-hail-jardiance-data-in-hard-to-treat-heart-failure/

News/ News/ Sales and Marketing

AZ closes in Forxiga kidney disease label in EU after nod from CHMP

Phil Taylor AstraZeneca, Boehringer Ingelheim, CHMP, chronic kidney disease, Eli Lilly, Farxiga, Forxiga, Jardiance 0 Comment

AstraZeneca’s fast-growing SGLT2 inhibitor Forxiga could soon get a further boost from approval in the EU as a

AZ closes in Forxiga kidney disease label in EU after nod from CHMP

https://pharmaphorum.com/news/az-closes-in-forxiga-kidney-disease-label-in-eu-after-nod-from-chmp/

News/ News/ Sales and Marketing

Farxiga faces first heart failure rival as EU OKs Boehringer/Lilly’s Jardiance

Phil Taylor AstraZeneca, Boehringer Ingelheim, cardiology, Eli Lilly, Farxiga, heart failure, Jardiance 0 Comment

AstraZeneca’s SGLT2 inhibitor Farxiga has been growing fast thanks to a first-in-class approval in heart failure, but will

Farxiga faces first heart failure rival as EU OKs Boehringer/Lilly’s Jardiance

https://pharmaphorum.com/news/farxiga-faces-first-heart-failure-rival-as-eu-oks-boehringer-lillys-jardiance/

Market Access/ News/ News

AstraZeneca’s Farxiga claims first SGLT2 kidney disease OK from FDA

Phil Taylor AstraZeneca, Boehringer Ingelheim, chronic kidney disease, Eli Lilly, Farxiga, fda, Jardiance, nephrology 0 Comment

AstraZeneca is already seeing sales rocket for its SGLT2 inhibitor Farxiga in heart failure, and is expected to

AstraZeneca’s Farxiga claims first SGLT2 kidney disease OK from FDA

https://pharmaphorum.com/news/astrazenecas-farxiga-gets-first-kidney-disease-ok-from-fda/

Trending

Jardiance

Login